In 2017, the US Food and Drug Administration approved second-line pembrolizumab —a drug targeting the immune-checkpoint programmed cell death protein 1— in any tumor, thus including breast cancer, showing MMR deficiency and/or high levels of microsatellite instability (MSI-H) (7). Here, MRC1 is linked to breast carcinoma.